

Table SI. Baseline characteristics of survey participants

	All participants <i>n</i> = 58	Mild ^a <i>n</i> = 9	Moderate ^a <i>n</i> = 23	Severe ^a <i>n</i> = 26	<i>p</i> -value ^b
Age, years, mean (range)	47 (23–70)	53 (43–66)	45 (23–70)	47 (26–69)	0.27
Female, <i>n</i> (%)	38 (66)	6 (67)	14 (61)	18 (69)	0.38
BMI, mean (range)	27.5 (19.8–48.1)	29 (24.7–39.7)	26 (20.8–37.5)	28 (19.8–48.1)	0.07
Living with psoriasis, years, mean (range)	19 (1–56)	15 (3–39)	18 (1–56)	22 (1–56)	0.35
Comorbidities, <i>n</i> (%)					
Any	22 (38)	6 (67)	9 (39)	7 (27)	
PSA	11 (19)	4 (44)	4 (17)	3 (12)	0.09
Depression)	7 (12)	1 (11)	4 (17)	2 (8)	0.81
Self-perceived severity, <i>n</i> (%)					
Mild	7 (12)	4 (44)	2 (8)	1 (4)	0.025 (correct classification)
Moderate	38 (66)	5 (56)	16 (70)	17 (65)	
Severe	13 (22)	0 (0)	5 (22)	8 (31)	
Psoriasis treatment, <i>n</i> (%)		^c	^d	^e	
None	24 (41)	4 (44)	11 (48)	9 (35)	
Topical	30 (52)	4 (44)	9 (39)	17 (65)	
Systemic	0 (0)	0	0	0	

^aSelf-estimated body surface area (BSA) affected by psoriasis. ^b*p*-value from χ^2 or one-way analysis of variance (ANOVA)/Kruskal–Wallis test, as appropriate. ^cOne answer missing. Topical category also includes non-prescription solutions (*n* = 1). ^dTwo answers missing. Topical category also includes non-prescription solutions (*n* = 1), and 1 subject used phototherapy. ^eTopical category also includes non-prescription solutions (*n* = 1).
 BMI: body mass index; PSA: psoriatic arthritis.